Vaishali Pharma
- Market cap
- ₹ 93 Cr.
- P/E
- 20.6x
- P/B
- 1.37x
- 52-week range
- 4.75 – 11.15
- ROE
- 6%
- ROCE
- 9%
- Dividend yield
- 0%
- Debt / equity
- 0.27
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE
About
Vaishali Pharma Limited is an India-based pharmaceutical company. The Company is in the pharmaceutical business, mainly dealing in active pharmaceutical ingredients, pharmaceutical formulations, surgical products, and veterinary supplements, operating in domestic and export markets. Its product categories include active pharmaceutical ingredients (APIs), formulation brands, formulations, herbal, nutraceutical, oncology, surgical, and veterinary. The Company has manufactured and exported approximately 250 formulations and specializes in manufacturing tailor-made formulations. It offers APIs, including antibiotics, anti-ulcer, anti-inflammatory/analgesic/ anti-pyretic, anti-malarial, cardiac, anti-diabetic, anti-cold/anti-allergic, antiviral, antifungal, skeletal muscle relaxant, and anthelmintic drugs, excipients, topical steroids, corticosteroids, and enzymes. It has a global presence in Asia & Pacific, Africa, the Commonwealth of Independent States, America, and the Middle East.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Vaishali Pharma against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.6 against a typical 34.3: cheaper than most peers (1st = cheapest).63rd of 220
- Sales growth−3.6% against a typical +15.6% from a year earlier.153rd of 197
- Profit growth+16.4% against a typical +18.9% from a year earlier.86th of 160
- Share price, 3 months−8.8% against a typical −0.5%.141st of 200
- Size₹ 92.7 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).150th of 199
Latest announcements
Exchange filings and their impact on the company.
- 45.4 lakh new preferential shares listed, adding ~3.5% shares and ~Rs 3.6 cr equity.
NSE has listed 45,37,865 new equity shares of Rs 2 each of Vaishali Pharma allotted on a preferential basis, with trading from October 16, 2026. The document does not disclose the issue price or use of funds. At the current price of about Rs 8, this implies roughly Rs 3.6 crore of new equity and about 3.5% dilution.
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 17 Oct 2026 | Preferential issue | Allotted | — | — | — |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 8 Jul 2026 | Fund Raising | To consider Fund Raising |
| 2 Jul 2026 | Fund Raising/Other business matters | To consider Fund Raising and other business matters |
| 30 May 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2026 and other business matters |
| 13 Feb 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended December 31, 2025 and other business matters |
| 14 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 13 | 28 | 32 | 18 | 21 | 28 | 32 | 24 | 33 | 25 | 27 | 23 |
| Expenses | 10 | 25 | 39 | 16 | 18 | 27 | 38 | 22 | 32 | 23 | 27 | 21 |
| Operating Profit | 3 | 3 | −7 | 2 | 2 | 1 | −6 | 1 | 1 | 2 | −0 | 1 |
| OPM % | 21.1% | 10.6% | −21% | 13% | 11.6% | 4.9% | −18.7% | 5.8% | 4.2% | 6.3% | −0.7% | 6.5% |
| Other Income | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | −6 | 2 | 3 | 2 | −6 | 2 | 2 | 2 | 0 | 2 |
| Tax % | 28% | 26.1% | −27% | 25.1% | 25.1% | 24.9% | −23.4% | 26.4% | 28.3% | 28.2% | −50% | 13.9% |
| Net Profit | 2 | 2 | −5 | 2 | 2 | 1 | −4 | 1 | 1 | 1 | 0 | 1 |
| EPS in Rs | 0.16 | 0.2 | −0.44 | 0.16 | 0.18 | 0.13 | −0.4 | 0.12 | 0.09 | 0.1 | 0.02 | 0.11 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 5%
- 5 Years
- 15%
- 3 Years
- 16%
- TTM
- 3%
- 10 Years
- 63%
- 5 Years
- 31%
- 3 Years
- −15%
- TTM
- 960%
- 10 Years
- —
- 5 Years
- 15%
- 3 Years
- −15%
- TTM
- —
- 10 Years
- 6%
- 5 Years
- 7%
- 3 Years
- 3%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Vaishali Pharma | ₹ 6.81 | ₹ 93 Cr. | 20.6x | 1.4x | 6% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Atul Vasani
- Chairman of the Board, Managing Director
- Hemanth Damodar Pathak
- Chief Executive Officer
- Dewansh Ajay Vasani
- Chief Financial Officer, Executive Director
- Akshay Jharkhandi
- Company Secretary & Compliance Officer
- Jagruti Vasani
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.